Additional file 2: of Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines
Olga Toro-Salazar
Ji Lee
Kia Zellars
Paige Perreault
Kathryn Mason
Zhu Wang
Kan Hor
Eileen Gillan
Caroline Zeiss
Daniel Gatti
Brooke Davey
Shelby Kutty
Bruce Liang
Francis Spinale
10.6084/m9.figshare.6204038.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_of_Use_of_integrated_imaging_and_serum_biomarker_profiles_to_identify_subclinical_dysfunction_in_pediatric_cancer_patients_treated_with_anthracyclines/6204038
Table S1. Plasma analytes assessed in referent normal subjects and in patients undergoing anthracycline therapy. Table S2. Linear regression of biomarkers at V1 to changes in Ejection Fraction >â10% from V1 to V6). (PDF 186 kb)
2018-05-01 05:00:00
Anthracyclines
Cardiotoxicity
Myocardial strain
Global systolic function